Paradigm Biopharmaceuticals Ltd. has released a press release.
Continuation of Voluntary Suspension
Earlier from Paradigm Biopharmaceuticals
- Agreement to Return US$2M to Obsidian
- Phase 3 Interim Result Below Continuation Threshold
- Suspension from Quotation
- Appendix 4E and 2026 Annual Report